Highlights

• Dr Ellen Feigal is serving on the Boards of NASDAQ-listed biotechnology companies Xencor Inc, and NextCure
• She has been included in Prescient Therapeutics' Board as a US-based independent, Non-Executive Director
• Dr Feigal has issued a statement saying she would "guide the business through the next phase of its growth"
• Chairman Steve Engle has lauded the “strong track record” of Dr Feigal in commercialisation of new cell-based treatments in the US and globally

ASX-listed clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has informed about the appointment of Dr Ellen Feigal to PTX's Board. Notably, Dr Feigal is an experienced pharma executive and has been onboarded as Prescient's US-based independent, Non-Executive Director. The effective date of her appointment is 15 May 2023.

Prescient Therapeutics is into the development of personalised therapies for treatment of cancer. Its targeted therapies include PTX-100 (blocks cancer growth enzyme geranylgeranyl transferase-1), and PTX 200 (inhibits tumour survival pathway Akt), while Prescient’s cell therapies include OmniCAR, and CellPryme-M and CellPryme-A.

Source: Company update 

More

The most recent development at the oncology company is related to the appointment of experienced pharma executive, Dr Ellen Feigal, to the company's Board. Dr Feigal brings to the table her expertise in development, commercialisation, and regulatory procedural aspects of cell therapies, hematology, and oncology. She has worked in leadership roles in industry as well as in academia and non-profits. 

Presently at NDA Partners LLC in the capacity of a Partner and Head of the Biologics practice, she oversees designing and implementation of product development and regulatory strategies. Her work here relates to cell therapies, medical imaging, and other related aspects. Dr Feigal also teaches FDA drug law and medical research ethics and law at the Sandra Day O’Connor College of Law, Arizona State University. 

Source: Company update 

Formerly, she worked as the Senior Vice President at California Institute of Regenerative Medicine (a foundation working toward developing new disease modifying treatments for chronic diseases). She has also worked in senior roles at the Amgen Inc (NASDAQ:AMGN), the Translational Genomics Research Institute, and the National Cancer Institute.

Dr Feigal is on the Board of Xencor Inc (NASDAQ:XNCR), which is developing engineered antibodies and cytokines to treat cancer and autoimmune diseases, besides being a board member at NextCure (NASDAQ:NXTC), which is developing new immunotherapies for the treatment of cancer.

Prescient's shares on ASX traded at AU$0.085 (market cap over AU$71 million) on 15 May 2023.